Newsletter | October 28, 2022

10.28.22 -- Innovative Solutions For mRNA, Bispecific Antibodies, Viral Vectors, And More

The Critical Role Of CDMOs In Driving Biomanufacturing Resilience

As a growing pipeline of novel product types commands existing capacity, sponsors must embrace strategies that will reimagine and reinforce resilience in today’s biomanufacturing ecosystem. CDMOs play a critical role in this effort, as innovators can utilize the advantages of these collaborations from an early stage until they are more assured of the future of their projects.

Optimization Of A Two-Step Purification Method For Bispecific Antibodies

Bispecific antibodies (bsAbs) have gained increasing interest over recent years because they can bind two antigens, offering unique modes of action compared to monoclonal antibodies. This article describes the further development of a two-step purification process of a bsAb.

Infographic: mRNA Manufacturing Workflow

mRNA-based therapeutics offer precise and individualized therapies and avoid manufacturing issues associated with recombinant proteins. Additionally, compared with current therapeutics, mRNA is faster, flexible, and more cost-effective to produce. Learn more about key objectives, considerations, and strategies in mRNA manufacturing.

Preparing For Future Viral Vector Manufacturing Technologies And Platforms

We need to industrialize and rethink how we transition from translational clinical centers at smaller scale toward commercial production and methodologies. How can we improve efficiency in virus production? How can we change from planar surfaces into 3D culture and suspension to reach the higher scales that clinical trials and commercial products will require?

Simplify Bioreactor Scale-Up And Scale-Down

In this article, we give an overview of the theory of scaling. Next, we present workflows and strategies and discuss which data are needed for successful scaling. Then, we introduce a scaling tool developed by Cytiva and present several case studies using the tool.

The Right Intensification Strategy For Upstream And Downstream Processes

How do you know if an intensification approach will give you advantages over your current biomanufacturing process, and how do you choose the right one? Three process intensification experts show how different intensification approaches affect outputs using different scenarios.

Biopharma Resilience: Bionova Scientific Talks Capacity, Speed, And Agility Needs

The COVID-19 pandemic was a worldwide lesson on the importance of flexibility and agility required for today's manufacturers to respond to demands for life-changing therapeutics. Bionova Scientific shares how a CDMO can offer biopharma companies the flexible capacity they need to meet the growing demands for medicines today and in the future.

Request Information
What’s Driving The Cell And Gene Therapy Outsourcing Capacity Cycle?

The feared, then realized, capacity shortage in the cell and gene therapy outsourcing space appears to be abating. But the market — and economy — remain in flux. We could be heading for overcapacity for some services but remain constricted in others. Our Outsourced Pharma Live event will discuss what to be on the lookout for as well as how to prepare and take advantage of (another) "life cycle" in our industry — this time in the cell and gene therapy space.

Innovative Biologics Solutions For CDMOs

Cytiva is a global provider of innovative technologies and services that help CDMOs and their end customers advance and accelerate the development and manufacture of therapeutics. Cytiva brings speed, efficiency, and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients. Click here to view their resources on supporting CDMOs with biologics manufacturing and process development.

In The News